The DSHB announces a new awards
program to support collaborative projects that will provide context to a “DSHB
Atlas”. The DSHB Atlas will map the reactivity of DSHB mAbs during
embryogenesis, development, and cellular differentiation. It will also cover model
systems such as Drosophila, and in vitro systems that include
cancer-related preparations. The mAb applications may include
immunocytochemistry, immunohistochemistry, western blotting,
immunoprecipitation, ELISA, FACS, chromatin immunoprecipitation, functional
blocking and modulation, and other antibody technologies. The systems employed
and the mAbs tested should be of interest to a sizeable number of research
scientists. The DSHB Atlas is intended to increase awareness of research
scientists of the potential applications of DSHB mAbs, which are of high
quality and only $40 per ml. The DSHB Atlas will be accessible at the DSHB
website and is now being designed. Currently, the DSHB banks over 5,000
hybridomas. Many of these hybridomas were generated against human antigens as well as antigens from a diverse variety of other organisms, by
individual scientists worldwide and a number of institutional initiatives (e.g.,
NIH “Protein Capture Reagent Program”, PCRP; NCI “Clinical Proteomic
Technologies for Cancer Initiative”, CPTC; EMBL mAb initiative, AFFN; and the
Muscular Dystrophy Association initiative). Many of these mAbs are an untapped source
of valuable reagents awaiting discovery.
DSHB Collaborative Awards will be $25,000. The DSHB will also provide to
awardees supernatants of the mAbs that will be assessed. A proposal two pages
in length will be reviewed by a committee composed of scientists drawn from the
DSHB Board of Directors and Senior Research Associates in the DSHB. Two pilot
projects were funded noncompetitively in order to obtain a sense of what can be
accomplished, how the results can be incorporated into the Atlas, how the
applicant can publish the results, and the potential impact on mAb
distribution. DSHB scientific staff members will assist awardees both in the
acquisition of mAbs and in any technical problems that arise. We hope to fund
four of these collaborative awards each year. We are primarily interested in
studies that include a reasonable number of mAbs that will increase their use
as reliable and valuable reagents. The mission of the DSHB is not only to serve
as a bank for mAbs and other protein capture reagents, but as a low cost
distributor. The DSHB is self-funded, receiving no supporting funds from
private or government institutions. Because the DSHB distributes at cost, there
will be no funds for institutional overhead.
The DSHB Atlas should help distribution expand as the mAb collection
expands. If you have specific questions, please feel free to email firstname.lastname@example.org.
Application. The application should be no more than
two pages of text. Relevant references, figures and tables should be limited in
number, and not restricted by the limitation of two pages of text. The
application should include the following components:
Introduction and Background.
In this section, introduce the system to be studied, the state of knowledge
concerning the information to be gathered, the impact the study will have and
the expertise of the applicant in successfully completing the project.
Specific Goals. Articulate
the specific goals of the proposed study. In this section, cover the type and
number of DSHB mAbs or other protein capture reagents that will be
Methods. Outline the
specific methods that will be employed.
Anticipated Findings and Impact.
Articulate the expected results. Describe how the results would be communicated
at meetings and publications. Also describe the anticipated presentation of the
results in publications, presentations, and the DSHB Atlas.
Budget. Briefly outline how
the funds will be spent.
Present funding. Briefly
note any present funding or other assets that would add to this collaborative
Funding. The DSHB Collaborative Award is $25,000 for
a one year period. Funding will require a letter from an institutional representative
which states the funds are accepted with the knowledge that they contain no
funds for overhead. It should be noted that the DSHB is a National Resource
created by the NIH and housed at the University of Iowa, and self-funded exclusively
through minimal fees charged to cover distribution.
Submission and Review. Applications must be received
prior to February 1, 2019. The review panel will consist of three research
scientists who are members of the DSHB Board of Advisers and three Senior
Research Associates from the DSHB senior scientific staff. The review process
may entail a phone communication between a Review Panel member and applicant,
if questions arise concerning the proposal. Decisions will be announced by
March 1, 2019.
Pilot Projects. To assess the feasibility of the DSHB
Collaborative Awards program, two pilot projects were developed that were
non-competitive. The two awardees are working closely with the DSHB research
staff in order to assess expectations and problems that may arise with the
award model we have developed.
New Antibody Tools for Exploring
Transcriptional Regulation of Neuroimmune Cell Development and Function in
Michael Dailey, Department of Biology, University of Iowa
Antibody Tools for Investigating
Protein Expressions in Mammalian Lens Development
Salil Lachke, Department of Biological Sciences, University of Delaware
applications to the Director. Email applications to email@example.com.